{"transactions":[{"id":994422,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-19T21:10:21.000Z","date":"2025-11-17","kind":"grant","planned":false,"acquired":true,"shares":137330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025."}],"balance_after":137330,"derivative":{"exercise_price":0.9548,"expiration_date":"2035-11-17","underlying":"Common Stock","underlying_shares":137330},"source":{"system":"sec-edgar","filing":"0001270905-25-000003","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000127090525000003/primary_doc.xml","form_type":"4"}},{"id":994421,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-19T21:10:21.000Z","date":"2025-11-17","kind":"grant","planned":false,"acquired":true,"shares":84411,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025."}],"balance_after":84411,"derivative":{"exercise_price":0.9548,"expiration_date":"2035-11-17","underlying":"Common Stock","underlying_shares":84411},"source":{"system":"sec-edgar","filing":"0001270905-25-000003","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000127090525000003/primary_doc.xml","form_type":"4"}},{"id":1268098,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-02-14T22:18:35.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date subject to the Reporting Person's continued service as a director. The option exercise price is the closing price on the date of the grant, February 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan. One third of the shares vest on the first anniversary of the grant date and the remainder of the shares subsequently vest in equal annual installments over the second and third anniversary of the grant date subject to the Reporting Person's continued service as a director. The option exercise price is the closing price on the date of the grant, February 12, 2025."}],"balance_after":30000,"derivative":{"exercise_price":1.59,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-25-014317","document":"tm256716-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925014317/tm256716-5_4seq1.xml","form_type":"4"}},{"id":1862924,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-09T01:35:39.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests on June 6, 2024, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":8000,"derivative":{"exercise_price":1.72,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-23-035617","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123035617/doc4.xml","form_type":"4"}},{"id":1862923,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T01:35:39.000Z","date":"2021-03-25","kind":"gift","planned":false,"acquired":true,"shares":7142,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By the Scott Eansor 2020 Exempt Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 10-1 reverse stock split which became effective on January 16, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 10-1 reverse stock split which became effective on January 16, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person transferred these shares to a trust of which the Reporting Person is the trustee. The Reporting Person's immediate family is the sole beneficiary of the trust."}],"balance_after":7142,"source":{"system":"sec-edgar","filing":"0001209191-23-035617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123035617/doc4.xml","form_type":"4"}},{"id":1862922,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T01:35:39.000Z","date":"2021-03-25","kind":"gift","planned":false,"acquired":true,"shares":7142,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By the John R. Eansor 2020 Exempt Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 10-1 reverse stock split which became effective on January 16, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 10-1 reverse stock split which became effective on January 16, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person transferred these shares to a trust of which the Reporting Person is the trustee. The Reporting Person's immediate family is the sole beneficiary of the trust."}],"balance_after":7142,"source":{"system":"sec-edgar","filing":"0001209191-23-035617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123035617/doc4.xml","form_type":"4"}},{"id":1862921,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T01:35:39.000Z","date":"2021-03-25","kind":"gift","planned":false,"acquired":false,"shares":14285,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 10-1 reverse stock split which became effective on January 16, 2023."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Reporting Person transferred these shares to a trust of which the Reporting Person is the trustee. The Reporting Person's immediate family is the sole beneficiary of the trust."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 10-1 reverse stock split which became effective on January 16, 2023."}],"balance_after":2428,"source":{"system":"sec-edgar","filing":"0001209191-23-035617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123035617/doc4.xml","form_type":"4"}},{"id":1862920,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T01:35:39.000Z","date":"2021-03-16","kind":"purchase","planned":false,"acquired":true,"shares":14285,"price":17.5,"value":249987.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 10-1 reverse stock split which became effective on January 16, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects a 10-1 reverse stock split which became effective on January 16, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 10-1 reverse stock split which became effective on January 16, 2023."}],"balance_after":16713,"source":{"system":"sec-edgar","filing":"0001209191-23-035617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919123035617/doc4.xml","form_type":"4"}},{"id":2255697,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-26T20:08:18.000Z","date":"2022-05-24","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests on May 24, 2023, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":80000,"derivative":{"exercise_price":0.3377,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-22-032166","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919122032166/doc4.xml","form_type":"4"}},{"id":2511857,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Stock Options (Right to Buy)","published_at":"2021-11-16T21:51:43.000Z","date":"2021-11-16","kind":"exercise","acquired":false,"shares":799,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Fully exercisable."}],"balance_after":0,"derivative":{"exercise_price":125.05,"expiration_date":"2024-08-09","underlying":"Common Stock","underlying_shares":799},"source":{"system":"sec-edgar","filing":"0000914190-21-000405","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000405/edgar.xml","form_type":"4"}},{"id":2511856,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Stock Options (Right to Buy)","published_at":"2021-11-16T21:51:43.000Z","date":"2021-11-12","kind":"exercise","acquired":false,"shares":27159,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Fully exercisable."}],"balance_after":799,"derivative":{"exercise_price":125.05,"expiration_date":"2024-08-09","underlying":"Common Stock","underlying_shares":27159},"source":{"system":"sec-edgar","filing":"0000914190-21-000405","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000405/edgar.xml","form_type":"4"}},{"id":2511855,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-11-16T21:51:43.000Z","date":"2021-11-16","kind":"exercise","acquired":true,"shares":799,"price":125.05,"value":99914.95,"ownership":{"direct":true},"balance_after":2117,"source":{"system":"sec-edgar","filing":"0000914190-21-000405","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000405/edgar.xml","form_type":"4"}},{"id":2511854,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-11-16T21:51:43.000Z","date":"2021-11-12","kind":"sale","acquired":false,"shares":401,"price":506.2399,"value":203002.1999,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $506.20 to $506.275, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1318,"source":{"system":"sec-edgar","filing":"0000914190-21-000405","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000405/edgar.xml","form_type":"4"}},{"id":2511853,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-11-16T21:51:43.000Z","date":"2021-11-12","kind":"sale","acquired":false,"shares":2535,"price":505.4861,"value":1281407.2635,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.13 to $506.07, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1719,"source":{"system":"sec-edgar","filing":"0000914190-21-000405","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000405/edgar.xml","form_type":"4"}},{"id":2511852,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-11-16T21:51:43.000Z","date":"2021-11-12","kind":"sale","acquired":false,"shares":8989,"price":504.3926,"value":4533985.0814,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.13 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":4254,"source":{"system":"sec-edgar","filing":"0000914190-21-000405","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000405/edgar.xml","form_type":"4"}},{"id":2511851,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-11-16T21:51:43.000Z","date":"2021-11-12","kind":"sale","acquired":false,"shares":9043,"price":503.6091,"value":4554137.0913,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.11 to $504.107, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":13243,"source":{"system":"sec-edgar","filing":"0000914190-21-000405","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000405/edgar.xml","form_type":"4"}},{"id":2511850,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-11-16T21:51:43.000Z","date":"2021-11-12","kind":"sale","acquired":false,"shares":4054,"price":502.7678,"value":2038220.6612,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.11 to $503.10, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":22286,"source":{"system":"sec-edgar","filing":"0000914190-21-000405","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000405/edgar.xml","form_type":"4"}},{"id":2511849,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-11-16T21:51:43.000Z","date":"2021-11-12","kind":"sale","acquired":false,"shares":400,"price":505.005,"value":202002.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.97 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":26340,"source":{"system":"sec-edgar","filing":"0000914190-21-000405","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000405/edgar.xml","form_type":"4"}},{"id":2511848,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-11-16T21:51:43.000Z","date":"2021-11-12","kind":"sale","acquired":false,"shares":537,"price":504.1437,"value":270725.1669,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.77 to $504.745, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":26740,"source":{"system":"sec-edgar","filing":"0000914190-21-000405","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000405/edgar.xml","form_type":"4"}},{"id":2511847,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-11-16T21:51:43.000Z","date":"2021-11-12","kind":"sale","acquired":false,"shares":300,"price":502.99,"value":150897.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.62 to $503.33, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":27277,"source":{"system":"sec-edgar","filing":"0000914190-21-000405","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000405/edgar.xml","form_type":"4"}},{"id":2511846,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-11-16T21:51:43.000Z","date":"2021-11-12","kind":"sale","acquired":false,"shares":200,"price":504.78,"value":100956.0,"ownership":{"direct":true},"balance_after":27577,"source":{"system":"sec-edgar","filing":"0000914190-21-000405","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000405/edgar.xml","form_type":"4"}},{"id":2511845,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-11-16T21:51:43.000Z","date":"2021-11-12","kind":"sale","acquired":false,"shares":700,"price":504.0864,"value":352860.48,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.78 to $504.535, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":27777,"source":{"system":"sec-edgar","filing":"0000914190-21-000405","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000405/edgar.xml","form_type":"4"}},{"id":2511844,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-11-16T21:51:43.000Z","date":"2021-11-12","kind":"exercise","acquired":true,"shares":27159,"price":125.05,"value":3396232.95,"ownership":{"direct":true},"balance_after":28477,"source":{"system":"sec-edgar","filing":"0000914190-21-000405","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000405/edgar.xml","form_type":"4"}},{"id":2582675,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-09-02T20:49:11.000Z","date":"2021-08-31","kind":"sale","acquired":false,"shares":1538,"price":503.0739,"value":773727.6582,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.941 to $503.315, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1318,"source":{"system":"sec-edgar","filing":"0000914190-21-000322","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000322/edgar.xml","form_type":"4"}},{"id":2609273,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Stock Options (Right to Buy)","published_at":"2021-08-10T22:19:54.000Z","date":"2021-08-06","kind":"grant","acquired":true,"shares":8107,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Options to purchase 2,027 shares vest on each of 8/6/2022, 8/6/2023 and 8/6/2024 and options to purchase 2,026 shares vest on 8/6/2025."}],"balance_after":8107,"derivative":{"exercise_price":481.82,"expiration_date":"2028-08-06","underlying":"Common Stock","underlying_shares":8107},"source":{"system":"sec-edgar","filing":"0000914190-21-000213","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000213/edgar.xml","form_type":"4"}},{"id":2609272,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Stock Options (Right to Buy)","published_at":"2021-08-10T22:19:54.000Z","date":"2021-08-06","kind":"grant","acquired":true,"shares":6080,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator)."}],"balance_after":6080,"derivative":{"exercise_price":481.82,"expiration_date":"2028-08-06","underlying":"Common Stock","underlying_shares":6080},"source":{"system":"sec-edgar","filing":"0000914190-21-000213","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000213/edgar.xml","form_type":"4"}},{"id":2609271,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Restricted Stock Units","published_at":"2021-08-10T22:19:54.000Z","date":"2021-08-06","kind":"grant","acquired":true,"shares":1556,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator)."}],"balance_after":1556,"derivative":{"underlying":"Common Stock","underlying_shares":1556},"source":{"system":"sec-edgar","filing":"0000914190-21-000213","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000213/edgar.xml","form_type":"4"}},{"id":2609270,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Restricted Stock Units","published_at":"2021-08-10T22:19:54.000Z","date":"2021-08-08","kind":"exercise","acquired":false,"shares":2537,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Vested in full on 8/8/2021 upon the certification of achievement of performance goals."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Vested in full on 8/8/2021 upon the certification of achievement of performance goals."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2537},"source":{"system":"sec-edgar","filing":"0000914190-21-000213","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000213/edgar.xml","form_type":"4"}},{"id":2609269,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-08-10T22:19:54.000Z","date":"2021-08-08","kind":"tax_withholding","acquired":false,"shares":999,"price":481.82,"value":481338.18,"ownership":{"direct":true},"balance_after":2856,"source":{"system":"sec-edgar","filing":"0000914190-21-000213","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000213/edgar.xml","form_type":"4"}},{"id":2609268,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-08-10T22:19:54.000Z","date":"2021-08-08","kind":"exercise","acquired":true,"shares":2537,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3855,"source":{"system":"sec-edgar","filing":"0000914190-21-000213","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000213/edgar.xml","form_type":"4"}},{"id":2674436,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-10T22:54:11.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":12658,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the Company's 2020 Equity Incentive Plan and based on the closing price of $3.16 per share, on the day immediately preceding the date of the Company's 2021 annual meeting."}],"balance_after":36940,"source":{"system":"sec-edgar","filing":"0001209191-21-039631","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121039631/doc4.xml","form_type":"4"}},{"id":2864246,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-12T22:11:45.000Z","date":"2020-05-19","kind":"grant","acquired":true,"shares":17022,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the\nCompany's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $2.35 per share, on the day immediately\npreceding the date of the Company's 2019 annual meeting."}],"balance_after":24282,"source":{"system":"sec-edgar","filing":"0001209191-21-010224","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000120919121010224/doc5.xml","form_type":"5"}},{"id":2873107,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Stock Options (Right to Buy)","published_at":"2021-02-09T22:24:13.000Z","date":"2021-02-05","kind":"exercise","acquired":false,"shares":18819,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Fully exercisable."}],"balance_after":0,"derivative":{"exercise_price":106.59,"expiration_date":"2023-08-18","underlying":"Common Stock","underlying_shares":18819},"source":{"system":"sec-edgar","filing":"0000914190-21-000037","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000037/edgar.xml","form_type":"4"}},{"id":2873106,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Stock Options (Right to Buy)","published_at":"2021-02-09T22:24:13.000Z","date":"2021-02-05","kind":"exercise","acquired":false,"shares":14114,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Fully exercisable."}],"balance_after":0,"derivative":{"exercise_price":106.59,"expiration_date":"2023-08-18","underlying":"Common Stock","underlying_shares":14114},"source":{"system":"sec-edgar","filing":"0000914190-21-000037","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000037/edgar.xml","form_type":"4"}},{"id":2873105,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-02-09T22:24:13.000Z","date":"2021-02-05","kind":"sale","acquired":false,"shares":1100,"price":385.5918,"value":424150.98,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $385.415 to $385.77, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1318,"source":{"system":"sec-edgar","filing":"0000914190-21-000037","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000037/edgar.xml","form_type":"4"}},{"id":2873104,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-02-09T22:24:13.000Z","date":"2021-02-05","kind":"sale","acquired":false,"shares":1900,"price":384.1518,"value":729888.42,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $383.93 to $384.39, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2418,"source":{"system":"sec-edgar","filing":"0000914190-21-000037","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000037/edgar.xml","form_type":"4"}},{"id":2873103,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-02-09T22:24:13.000Z","date":"2021-02-05","kind":"sale","acquired":false,"shares":3700,"price":382.6043,"value":1415635.91,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $382.26 to $383.07, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":4318,"source":{"system":"sec-edgar","filing":"0000914190-21-000037","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000037/edgar.xml","form_type":"4"}},{"id":2873102,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-02-09T22:24:13.000Z","date":"2021-02-05","kind":"sale","acquired":false,"shares":2900,"price":381.5155,"value":1106394.95,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $381.095 to $382.01, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":8018,"source":{"system":"sec-edgar","filing":"0000914190-21-000037","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000037/edgar.xml","form_type":"4"}},{"id":2873101,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-02-09T22:24:13.000Z","date":"2021-02-05","kind":"sale","acquired":false,"shares":12833,"price":380.497,"value":4882918.001,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $380.065 to $381.055, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":10918,"source":{"system":"sec-edgar","filing":"0000914190-21-000037","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000037/edgar.xml","form_type":"4"}},{"id":2873100,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-02-09T22:24:13.000Z","date":"2021-02-05","kind":"sale","acquired":false,"shares":4500,"price":379.6249,"value":1708312.05,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $379.03 to $380.01, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":23751,"source":{"system":"sec-edgar","filing":"0000914190-21-000037","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000037/edgar.xml","form_type":"4"}},{"id":2873099,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-02-09T22:24:13.000Z","date":"2021-02-05","kind":"sale","acquired":false,"shares":6000,"price":378.2871,"value":2269722.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $378.00 to $378.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":28251,"source":{"system":"sec-edgar","filing":"0000914190-21-000037","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000037/edgar.xml","form_type":"4"}},{"id":2873098,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-02-09T22:24:13.000Z","date":"2021-02-05","kind":"exercise","acquired":true,"shares":18819,"price":106.59,"value":2005917.21,"ownership":{"direct":true},"balance_after":34251,"source":{"system":"sec-edgar","filing":"0000914190-21-000037","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000037/edgar.xml","form_type":"4"}},{"id":2873097,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2021-02-09T22:24:13.000Z","date":"2021-02-05","kind":"exercise","acquired":true,"shares":14114,"price":106.59,"value":1504411.26,"ownership":{"direct":true},"balance_after":15432,"source":{"system":"sec-edgar","filing":"0000914190-21-000037","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419021000037/edgar.xml","form_type":"4"}},{"id":3062530,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Restricted Stock Units","published_at":"2020-08-11T22:21:51.000Z","date":"2020-08-09","kind":"exercise","acquired":false,"shares":2174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On 8/9/2020, the Board of Directors certified vesting of 2,174 performance RSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On 8/9/2020, the Board of Directors certified vesting of 2,174 performance RSUs."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2174},"source":{"system":"sec-edgar","filing":"0000914190-20-000291","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000291/edgar.xml","form_type":"4"}},{"id":3062529,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2020-08-11T22:21:51.000Z","date":"2020-08-09","kind":"tax_withholding","acquired":false,"shares":856,"price":265.76,"value":227490.56,"ownership":{"direct":true},"balance_after":1318,"source":{"system":"sec-edgar","filing":"0000914190-20-000291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000291/edgar.xml","form_type":"4"}},{"id":3062528,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2020-08-11T22:21:51.000Z","date":"2020-08-09","kind":"exercise","acquired":true,"shares":2174,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2174,"source":{"system":"sec-edgar","filing":"0000914190-20-000291","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000291/edgar.xml","form_type":"4"}},{"id":3065270,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-08-07T22:33:09.000Z","date":"2020-08-05","kind":"grant","acquired":true,"shares":24975,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"Options to purchase 8,325 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023."}],"balance_after":24975,"derivative":{"exercise_price":267.87,"expiration_date":"2027-08-05","underlying":"Common Stock","underlying_shares":24975},"source":{"system":"sec-edgar","filing":"0000914190-20-000245","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000245/edgar.xml","form_type":"4"}},{"id":3065269,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-08-07T22:33:09.000Z","date":"2020-08-05","kind":"grant","acquired":true,"shares":24975,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021"}],"balance_after":24975,"derivative":{"exercise_price":267.87,"expiration_date":"2027-08-05","underlying":"Common Stock","underlying_shares":24975},"source":{"system":"sec-edgar","filing":"0000914190-20-000245","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000245/edgar.xml","form_type":"4"}},{"id":3065268,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-08-07T22:33:09.000Z","date":"2020-08-05","kind":"grant","acquired":true,"shares":15318,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Options to purchase 3,830 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 3,829 shares vest on each of 8/5/2023 and 8/5/2024."}],"balance_after":15318,"derivative":{"exercise_price":267.87,"expiration_date":"2027-08-05","underlying":"Common Stock","underlying_shares":15318},"source":{"system":"sec-edgar","filing":"0000914190-20-000245","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000245/edgar.xml","form_type":"4"}},{"id":3065267,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-08-07T22:33:09.000Z","date":"2020-08-05","kind":"grant","acquired":true,"shares":11488,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator)."}],"balance_after":11488,"derivative":{"exercise_price":267.87,"expiration_date":"2027-08-05","underlying":"Common Stock","underlying_shares":11488},"source":{"system":"sec-edgar","filing":"0000914190-20-000245","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000245/edgar.xml","form_type":"4"}},{"id":3065266,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Restricted Stock Units","published_at":"2020-08-07T22:33:09.000Z","date":"2020-08-05","kind":"grant","acquired":true,"shares":2575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator)."}],"balance_after":2575,"derivative":{"underlying":"Common Stock","underlying_shares":2575},"source":{"system":"sec-edgar","filing":"0000914190-20-000245","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000245/edgar.xml","form_type":"4"}},{"id":3129781,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-06-01T21:58:18.000Z","date":"2020-05-29","kind":"exercise","acquired":false,"shares":7909,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Fully exercisable."}],"balance_after":0,"derivative":{"exercise_price":108.49,"expiration_date":"2022-08-07","underlying":"Common Stock","underlying_shares":7909},"source":{"system":"sec-edgar","filing":"0000914190-20-000195","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000195/edgar.xml","form_type":"4"}},{"id":3129780,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-06-01T21:58:18.000Z","date":"2020-05-28","kind":"exercise","acquired":false,"shares":3448,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Fully exercisable."}],"balance_after":7909,"derivative":{"exercise_price":108.49,"expiration_date":"2022-08-07","underlying":"Common Stock","underlying_shares":3448},"source":{"system":"sec-edgar","filing":"0000914190-20-000195","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000195/edgar.xml","form_type":"4"}},{"id":3129779,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2020-06-01T21:58:18.000Z","date":"2020-05-29","kind":"sale","acquired":false,"shares":709,"price":264.0119,"value":187184.4371,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.6168 to $264.5700, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000914190-20-000195","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000195/edgar.xml","form_type":"4"}},{"id":3129778,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2020-06-01T21:58:18.000Z","date":"2020-05-29","kind":"sale","acquired":false,"shares":2100,"price":262.6759,"value":551619.39,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $262.3150 to $263.2300, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":709,"source":{"system":"sec-edgar","filing":"0000914190-20-000195","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000195/edgar.xml","form_type":"4"}},{"id":3129777,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2020-06-01T21:58:18.000Z","date":"2020-05-29","kind":"sale","acquired":false,"shares":3400,"price":261.7431,"value":889926.54,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.2500 to $262.2400, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":2809,"source":{"system":"sec-edgar","filing":"0000914190-20-000195","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000195/edgar.xml","form_type":"4"}},{"id":3129776,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2020-06-01T21:58:18.000Z","date":"2020-05-29","kind":"sale","acquired":false,"shares":1700,"price":260.8292,"value":443409.64,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.2500 to $261.2100, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":6209,"source":{"system":"sec-edgar","filing":"0000914190-20-000195","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000195/edgar.xml","form_type":"4"}},{"id":3129775,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2020-06-01T21:58:18.000Z","date":"2020-05-29","kind":"exercise","acquired":true,"shares":7909,"price":108.49,"value":858047.41,"ownership":{"direct":true},"balance_after":7909,"source":{"system":"sec-edgar","filing":"0000914190-20-000195","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000195/edgar.xml","form_type":"4"}},{"id":3129774,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2020-06-01T21:58:18.000Z","date":"2020-05-28","kind":"sale","acquired":false,"shares":3448,"price":260.1897,"value":897134.0856,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.0000 to $260.6600, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000914190-20-000195","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000195/edgar.xml","form_type":"4"}},{"id":3129773,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2020-06-01T21:58:18.000Z","date":"2020-05-28","kind":"exercise","acquired":true,"shares":3448,"price":108.49,"value":374073.52,"ownership":{"direct":true},"balance_after":3448,"source":{"system":"sec-edgar","filing":"0000914190-20-000195","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000195/edgar.xml","form_type":"4"}},{"id":3135950,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-05-26T21:13:55.000Z","date":"2020-05-22","kind":"exercise","acquired":false,"shares":8637,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Fully exercisable."}],"balance_after":11357,"derivative":{"exercise_price":108.49,"expiration_date":"2022-08-07","underlying":"Common Stock","underlying_shares":8637},"source":{"system":"sec-edgar","filing":"0000914190-20-000183","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000183/edgar.xml","form_type":"4"}},{"id":3135949,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-05-26T21:13:55.000Z","date":"2020-05-22","kind":"exercise","acquired":false,"shares":3963,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Fully exercisable."}],"balance_after":0,"derivative":{"exercise_price":94.35,"expiration_date":"2021-08-12","underlying":"Common Stock","underlying_shares":3963},"source":{"system":"sec-edgar","filing":"0000914190-20-000183","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000183/edgar.xml","form_type":"4"}},{"id":3135948,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-05-26T21:13:55.000Z","date":"2020-05-21","kind":"exercise","acquired":false,"shares":11037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Fully exercisable."}],"balance_after":3963,"derivative":{"exercise_price":94.35,"expiration_date":"2021-08-12","underlying":"Common Stock","underlying_shares":11037},"source":{"system":"sec-edgar","filing":"0000914190-20-000183","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000183/edgar.xml","form_type":"4"}},{"id":3135947,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2020-05-26T21:13:55.000Z","date":"2020-05-22","kind":"sale","acquired":false,"shares":4924,"price":268.407,"value":1321636.068,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.09 to $268.81, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000914190-20-000183","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000183/edgar.xml","form_type":"4"}},{"id":3135946,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2020-05-26T21:13:55.000Z","date":"2020-05-22","kind":"sale","acquired":false,"shares":7676,"price":267.625,"value":2054289.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.09 to $268.05, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":4924,"source":{"system":"sec-edgar","filing":"0000914190-20-000183","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000183/edgar.xml","form_type":"4"}},{"id":3135945,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2020-05-26T21:13:55.000Z","date":"2020-05-22","kind":"exercise","acquired":true,"shares":8637,"price":108.49,"value":937028.13,"ownership":{"direct":true},"balance_after":12600,"source":{"system":"sec-edgar","filing":"0000914190-20-000183","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000183/edgar.xml","form_type":"4"}},{"id":3135944,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2020-05-26T21:13:55.000Z","date":"2020-05-22","kind":"exercise","acquired":true,"shares":3963,"price":94.35,"value":373909.05,"ownership":{"direct":true},"balance_after":3963,"source":{"system":"sec-edgar","filing":"0000914190-20-000183","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000183/edgar.xml","form_type":"4"}},{"id":3135943,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2020-05-26T21:13:55.000Z","date":"2020-05-21","kind":"sale","acquired":false,"shares":900,"price":268.885,"value":241996.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.58 to $269.32, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000914190-20-000183","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000183/edgar.xml","form_type":"4"}},{"id":3135942,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2020-05-26T21:13:55.000Z","date":"2020-05-21","kind":"sale","acquired":false,"shares":10137,"price":267.369,"value":2710319.553,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $267.02 to $267.75, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":900,"source":{"system":"sec-edgar","filing":"0000914190-20-000183","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000183/edgar.xml","form_type":"4"}},{"id":3135941,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2020-05-26T21:13:55.000Z","date":"2020-05-21","kind":"exercise","acquired":true,"shares":11037,"price":94.35,"value":1041340.95,"ownership":{"direct":true},"balance_after":11037,"source":{"system":"sec-edgar","filing":"0000914190-20-000183","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000183/edgar.xml","form_type":"4"}},{"id":3223532,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President-Protein Sciences"}}],"security":"Common Stock","published_at":"2020-03-06T21:08:40.000Z","date":"2020-03-04","kind":"sale","acquired":false,"shares":1387,"price":198.68,"value":275569.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.60 to $198.75, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000914190-20-000109","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419020000109/edgar.xml","form_type":"4"}},{"id":3432529,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Novus Biologicals"}}],"security":"Restricted Stock Units","published_at":"2019-08-21T20:34:28.000Z","date":"2019-08-19","kind":"exercise","acquired":false,"shares":2287,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On 8/19/2019, the Board of Directors certified vesting of 2,287 performance RSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On 8/19/2019, the Board of Directors certified vesting of 2,287 performance RSUs."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2287},"source":{"system":"sec-edgar","filing":"0000914190-19-000331","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419019000331/edgar.xml","form_type":"4"}},{"id":3432528,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Novus Biologicals"}}],"security":"Common Stock","published_at":"2019-08-21T20:34:28.000Z","date":"2019-08-19","kind":"tax_withholding","acquired":false,"shares":900,"price":197.57,"value":177813.0,"ownership":{"direct":true},"balance_after":1387,"source":{"system":"sec-edgar","filing":"0000914190-19-000331","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419019000331/edgar.xml","form_type":"4"}},{"id":3432527,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Novus Biologicals"}}],"security":"Common Stock","published_at":"2019-08-21T20:34:28.000Z","date":"2019-08-19","kind":"exercise","acquired":true,"shares":2287,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock."}],"balance_after":2287,"source":{"system":"sec-edgar","filing":"0000914190-19-000331","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419019000331/edgar.xml","form_type":"4"}},{"id":3442952,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Novus Biologicals"}}],"security":"Stock Options (Right to Buy)","published_at":"2019-08-09T20:11:44.000Z","date":"2019-08-07","kind":"grant","acquired":true,"shares":21265,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023."}],"balance_after":21265,"derivative":{"exercise_price":190.41,"expiration_date":"2026-08-07","underlying":"Common Stock","underlying_shares":21265},"source":{"system":"sec-edgar","filing":"0000914190-19-000260","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419019000260/edgar.xml","form_type":"4"}},{"id":3442951,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Novus Biologicals"}}],"security":"Stock Options (Right to Buy)","published_at":"2019-08-09T20:11:44.000Z","date":"2019-08-07","kind":"grant","acquired":true,"shares":15948,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator)."}],"balance_after":15948,"derivative":{"exercise_price":190.41,"expiration_date":"2026-08-07","underlying":"Common Stock","underlying_shares":15948},"source":{"system":"sec-edgar","filing":"0000914190-19-000260","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419019000260/edgar.xml","form_type":"4"}},{"id":3442950,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Novus Biologicals"}}],"security":"Restricted Stock Units","published_at":"2019-08-09T20:11:44.000Z","date":"2019-08-07","kind":"grant","acquired":true,"shares":3151,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator)."}],"balance_after":3151,"derivative":{"underlying":"Common Stock","underlying_shares":3151},"source":{"system":"sec-edgar","filing":"0000914190-19-000260","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/842023/000091419019000260/edgar.xml","form_type":"4"}},{"id":3490558,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Novus Biologicals"}}],"security":"Common Stock","published_at":"2019-06-14T20:13:36.000Z","date":"2019-06-12","kind":"sale","acquired":false,"shares":3117,"price":215,"value":670155.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2019."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-19-003526","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/842023/000156218019003526/primarydocument.xml","form_type":"4"}},{"id":3530301,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-13T20:02:13.000Z","date":"2019-05-09","kind":"grant","acquired":true,"shares":7260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of the annual board retainer for each non-employee director payable in immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $5.51 per share, on the day immediately preceding the date of the Company's 2019 annual meeting."}],"balance_after":7260,"source":{"system":"sec-edgar","filing":"0001144204-19-025608","document":"tv521409_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000114420419025608/tv521409_4.xml","form_type":"4"}},{"id":3786970,"issuer":{"id":7609,"kind":"organization","name":"Marker Therapeutics, Inc."},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Employee Director Stock Option (Right to Buy)","published_at":"2018-10-19T20:53:01.000Z","date":"2018-10-17","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended, in connection with the non-employee director compensation program upon appointment as a director of the Company on October 17, 2018.  These shares vest in monthly installments over a two year period.  The option exercise price is the closing price on the date of the grant, October 17, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended, in connection with the non-employee director compensation program upon appointment as a director of the Company on October 17, 2018.  These shares vest in monthly installments over a two year period.  The option exercise price is the closing price on the date of the grant, October 17, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended, in connection with the non-employee director compensation program upon appointment as a director of the Company on October 17, 2018.  These shares vest in monthly installments over a two year period.  The option exercise price is the closing price on the date of the grant, October 17, 2018."}],"balance_after":12500,"derivative":{"exercise_price":8.34,"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001144204-18-054586","document":"tv505080_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1094038/000114420418054586/tv505080_4.xml","form_type":"4"}},{"id":3849009,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Novus Biologicals"}}],"security":"Stock Options (Right to buy)","published_at":"2018-08-09T22:29:54.000Z","date":"2018-08-08","kind":"grant","acquired":true,"shares":13550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator)."}],"balance_after":13550,"derivative":{"exercise_price":177.32,"expiration_date":"2025-08-08","underlying":"Common Stock","underlying_shares":13550},"source":{"system":"sec-edgar","filing":"0001562180-18-003544","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/842023/000156218018003544/primarydocument.xml","form_type":"4"}},{"id":3849008,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Novus Biologicals"}}],"security":"Stock Options (Right to buy)","published_at":"2018-08-09T22:29:54.000Z","date":"2018-08-08","kind":"grant","acquired":true,"shares":18066,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Vests 4,517 shares each on 8/8/2019, 8/8/2020 and 4,516 shares each on 8/8/2021, 8/8/2022."}],"balance_after":18066,"derivative":{"exercise_price":177.32,"expiration_date":"2025-08-08","underlying":"Common Stock","underlying_shares":18066},"source":{"system":"sec-edgar","filing":"0001562180-18-003544","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/842023/000156218018003544/primarydocument.xml","form_type":"4"}},{"id":3849007,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Novus Biologicals"}}],"security":"Restricted Stock Units","published_at":"2018-08-09T22:29:54.000Z","date":"2018-08-08","kind":"grant","acquired":true,"shares":2537,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator)."}],"balance_after":2537,"derivative":{"underlying":"Common Stock","underlying_shares":2537},"source":{"system":"sec-edgar","filing":"0001562180-18-003544","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/842023/000156218018003544/primarydocument.xml","form_type":"4"}},{"id":3849006,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Novus Biologicals"}}],"security":"Stock Options (Right to buy)","published_at":"2018-08-09T22:29:54.000Z","date":"2018-08-07","kind":"disposition_to_issuer","acquired":false,"shares":1881,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On 8/7/2018, the Board of Directors authorized discretionary vesting for 7,494 performance options.  The remainder of the performance options were forfeited."}],"balance_after":7494,"derivative":{"exercise_price":108.49,"expiration_date":"2022-08-07","underlying":"Common Stock","underlying_shares":1881},"source":{"system":"sec-edgar","filing":"0001562180-18-003544","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/842023/000156218018003544/primarydocument.xml","form_type":"4"}},{"id":3849005,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Novus Biologicals"}}],"security":"Restricted Stock Units","published_at":"2018-08-09T22:29:54.000Z","date":"2018-08-07","kind":"disposition_to_issuer","acquired":false,"shares":301,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On 8/7/2018, the Board of Directors authorized discretionary vesting for 1,199 performance RSUs.  The remainder of the performance RSUs were forfeited."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On 8/7/2018, the Board of Directors authorized discretionary vesting for 1,199 performance RSUs.  The remainder of the performance RSUs were forfeited."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":301},"source":{"system":"sec-edgar","filing":"0001562180-18-003544","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/842023/000156218018003544/primarydocument.xml","form_type":"4"}},{"id":3849004,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Novus Biologicals"}}],"security":"Restricted Stock Units","published_at":"2018-08-09T22:29:54.000Z","date":"2018-08-07","kind":"exercise","acquired":false,"shares":1199,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On 8/7/2018, the Board of Directors authorized discretionary vesting for 1,199 performance RSUs.  The remainder of the performance RSUs were forfeited."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On 8/7/2018, the Board of Directors authorized discretionary vesting for 1,199 performance RSUs.  The remainder of the performance RSUs were forfeited."}],"balance_after":301,"derivative":{"underlying":"Common Stock","underlying_shares":1199},"source":{"system":"sec-edgar","filing":"0001562180-18-003544","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/842023/000156218018003544/primarydocument.xml","form_type":"4"}},{"id":3849003,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Novus Biologicals"}}],"security":"Common Stock","published_at":"2018-08-09T22:29:54.000Z","date":"2018-08-07","kind":"tax_withholding","acquired":false,"shares":348,"price":180.14,"value":62688.72,"ownership":{"direct":true},"balance_after":3117,"source":{"system":"sec-edgar","filing":"0001562180-18-003544","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/842023/000156218018003544/primarydocument.xml","form_type":"4"}},{"id":3849002,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Novus Biologicals"}}],"security":"Common Stock","published_at":"2018-08-09T22:29:54.000Z","date":"2018-08-07","kind":"exercise","acquired":true,"shares":1199,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3465,"source":{"system":"sec-edgar","filing":"0001562180-18-003544","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/842023/000156218018003544/primarydocument.xml","form_type":"4"}},{"id":3937971,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Novus Biologicals"}}],"security":"Common Stock","published_at":"2018-05-11T20:16:17.000Z","date":"2018-05-04","kind":"sale","acquired":false,"shares":1136,"price":145.1864,"value":164931.7504,"ownership":{"direct":true},"balance_after":2266,"source":{"system":"sec-edgar","filing":"0001562180-18-002455","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/842023/000156218018002455/primarydocument.xml","form_type":"4"}},{"id":4178918,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Novus Biologicals"}}],"security":"Stock Options (Right to buy)","published_at":"2017-10-30T20:56:25.000Z","date":"2017-10-26","kind":"grant","acquired":true,"shares":15976,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Vest 3,994 shares on each 8/9/2018, 8/9/2019, 8/9/2020, 8/9/2021"}],"balance_after":15976,"derivative":{"exercise_price":125.05,"expiration_date":"2024-08-09","underlying":"Common Stock","underlying_shares":15976},"source":{"system":"sec-edgar","filing":"0001562180-17-003379","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/842023/000156218017003379/primarydocument.xml","form_type":"4"}},{"id":4178917,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Novus Biologicals"}}],"security":"Stock Options (Right to buy)","published_at":"2017-10-30T20:56:25.000Z","date":"2017-10-26","kind":"grant","acquired":true,"shares":11982,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator)."}],"balance_after":11982,"derivative":{"exercise_price":125.05,"expiration_date":"2024-08-09","underlying":"Common Stock","underlying_shares":11982},"source":{"system":"sec-edgar","filing":"0001562180-17-003379","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/842023/000156218017003379/primarydocument.xml","form_type":"4"}},{"id":4178916,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Novus Biologicals"}}],"security":"Restricted Stock Units","published_at":"2017-10-30T20:56:25.000Z","date":"2017-10-26","kind":"grant","acquired":true,"shares":2174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator)."}],"balance_after":2174,"derivative":{"underlying":"Common Stock","underlying_shares":2174},"source":{"system":"sec-edgar","filing":"0001562180-17-003379","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/842023/000156218017003379/primarydocument.xml","form_type":"4"}},{"id":4266232,"issuer":{"id":3479,"kind":"organization","name":"BIO-TECHNE Corp","symbol":"TECH"},"owners":[{"id":72912,"kind":"person","name":"Eansor Norman David","position":1,"cik":"0001270905","reported_name":"Eansor Norman David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Novus Biologicals"}}],"security":"Common Stock","published_at":"2017-07-05T21:46:20.000Z","date":"2017-07-01","kind":"tax_withholding","acquired":false,"shares":534,"price":117.5,"value":62745.0,"ownership":{"direct":true},"balance_after":3402,"source":{"system":"sec-edgar","filing":"0001562180-17-002413","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/842023/000156218017002413/primarydocument.xml","form_type":"4"}}]}